The Experts below are selected from a list of 5832 Experts worldwide ranked by ideXlab platform

Allison L. Naleway - One of the best experts on this subject based on the ideXlab platform.

Simon J. Hambidge - One of the best experts on this subject based on the ideXlab platform.

Margaret B. Rennels - One of the best experts on this subject based on the ideXlab platform.

  • safety reactogenicity and immunogenicity of a tetravalent meningococcal polysaccharide Diphtheria Toxoid conjugate vaccine given to healthy adults
    The Journal of Infectious Diseases, 2002
    Co-Authors: James D. Campbell, Robert R. Edelman, James C. King, Thomas Papa, Robert P Ryall, Margaret B. Rennels
    Abstract:

    Healthy adults, 18-55 years old, were immunized once with a tetravalent (serogroups A, C, Y, and W-135) meningococcal vaccine conjugated to Diphtheria Toxoid at 1 of 3 doses and were monitored for safety, reactogenicity, and immunogenicity. No immediate reactions were observed. Only 1 of 89 subjects reported fever; only 1 reported any severe reactogenicity (local pain/soreness, chills, arthralgia, anorexia, and malaise). For each serogroup and in each dose group, the geometric mean serum bactericidal antibody (SBA) titer and immunoglobulin G concentration increased after immunization. In the 4- and 10-microg-dose groups, all subjects had SBA titers >/=8 against serogroups A and C, and 89% and 93% of subjects had SBA titers >/=8 against serogroups Y and W-135, respectively. The A, C, Y, and W-135 Neisseria meningitidis-Diphtheria Toxoid conjugate vaccine, when given to healthy adults as a single intramuscular injection of 1, 4, or 10 microg/serogroup, is acceptably tolerated and immunogenic and deserves further development.

  • Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy Adults
    The Journal of infectious diseases, 2002
    Co-Authors: James D. Campbell, Robert R. Edelman, James C. King, Thomas Papa, Ryall Robert P, Margaret B. Rennels
    Abstract:

    Healthy adults, 18-55 years old, were immunized once with a tetravalent (serogroups A, C, Y, and W-135) meningococcal vaccine conjugated to Diphtheria Toxoid at 1 of 3 doses and were monitored for safety, reactogenicity, and immunogenicity. No immediate reactions were observed. Only 1 of 89 subjects reported fever; only 1 reported any severe reactogenicity (local pain/soreness, chills, arthralgia, anorexia, and malaise). For each serogroup and in each dose group, the geometric mean serum bactericidal antibody (SBA) titer and immunoglobulin G concentration increased after immunization. In the 4- and 10-microg-dose groups, all subjects had SBA titers >/=8 against serogroups A and C, and 89% and 93% of subjects had SBA titers >/=8 against serogroups Y and W-135, respectively. The A, C, Y, and W-135 Neisseria meningitidis-Diphtheria Toxoid conjugate vaccine, when given to healthy adults as a single intramuscular injection of 1, 4, or 10 microg/serogroup, is acceptably tolerated and immunogenic and deserves further development.

Gideon F.a. Kersten - One of the best experts on this subject based on the ideXlab platform.

  • antigenic fingerprinting of Diphtheria Toxoid adsorbed to aluminium phosphate
    Biologicals, 2017
    Co-Authors: Janny Westdijk, Bernard Metz, Nanda Spruit, Wichard Tilstra, Coenradus F.m. Hendriksen, Gideon F.a. Kersten
    Abstract:

    The antigenicity of alum-adsorbed Diphtheria Toxoid (DTd) was determined in combination vaccines, containing DTd, tetanus Toxoid and inactivated poliovirus. A panel of monoclonal antibodies was used, covering five epitopes, distributed over the antigen. The resulting antigenic fingerprint of DTd demonstrates consistency of adsorption at antigen level in final product combination vaccines. The antigenic quality of DTd alone, adsorbed to aluminium phosphate, was also determined and compared with pre-adsorbed Toxoid (starting material as well as Toxoid desorbed from aluminium phosphate). Some epitopes became less accessible after adsorption, while others became relatively better exposed. Some epitopes disappeared almost completely upon adsorption, but were re-established after desorption of the antigen. The results indicate that DTd is adsorbed to aluminium phosphate in a preferred orientation and not randomly.

  • Structural perturbation of Diphtheria Toxoid upon adsorption to aluminium hydroxide adjuvant
    Vaccine, 2012
    Co-Authors: Marie Régnier, Bernard Metz, Wichard Tilstra, Coenraad F.m. Hendriksen, Wim Jiskoot, Willem Norde, Gideon F.a. Kersten
    Abstract:

    Aluminium-containing adjuvants are often used to enhance the potency of vaccines. In the present work we studied whether adsorption of Diphtheria Toxoid to colloidal aluminium hydroxide induces conformational changes of the antigen. Diphtheria Toxoid has a high affinity for the aluminium hydroxide particles based on a high adsorption degree, adsorption rate and adsorptive capacity. The conformation and stability of Diphtheria Toxoid in solution and adsorbed to aluminium hydroxide adjuvant were characterized using five physicochemical techniques: intrinsic and extrinsic fluorescence spectroscopy, circular dichroism, infrared spectroscopy and differential scanning calorimetry. Diphtheria Toxoid adsorbed to aluminium hydroxide resulted in a minimal shift of the tryptophan fluorescence spectrum, whereas a large increase in the emission of the Bis-ANS probe was observed, indicating that hydrophobic sites of the protein became accessible due to adsorption. In addition, circular dichroism and infrared spectroscopy revealed that adsorption to aluminium hydroxide caused an increase of β-sheet content and a decrease of α-helix content in Diphtheria Toxoid. Differential scanning calorimetry demonstrated a major decrease in the enthalpy of denaturation upon adsorption. In conclusion, the adsorption of Diphtheria Toxoid to aluminium hydroxide adjuvant leads to substantial conformational changes in the antigen. Since physicochemical methods can be used to monitor these conformational changes, these analytical methods might offer a tool in regulatory required vaccine quality control by demonstrating consistency in production.

  • Microneedle-Based Transcutaneous Immunisation in Mice with N-Trimethyl Chitosan Adjuvanted Diphtheria Toxoid Formulations
    Pharmaceutical research, 2010
    Co-Authors: Suzanne M. Bal, Gideon F.a. Kersten, Wim Jiskoot, Zhi-shan Ding, Joke A. Bouwstra
    Abstract:

    Purpose The purpose of this study was to gain insight into the delivery and immunogenicity of N-trimethyl chitosan (TMC) adjuvanted Diphtheria Toxoid (DT) formulations applied transcutaneously with microneedles.

  • Transcutaneous Immunization Studies in Mice Using Diphtheria Toxoid-Loaded Vesicle Formulations and a Microneedle Array
    Pharmaceutical research, 2010
    Co-Authors: Zhi Ding, Gideon F.a. Kersten, Wim Jiskoot, Suzanne M. Bal, Stefan Romeijn, Joke A. Bouwstra
    Abstract:

    Purpose To determine the immunogenicity of Diphtheria Toxoid (DT) formulated in two types of vesicles following transcutaneous immunization (TCI) of mice onto microneedle array-treated skin.

  • Immune modulation by adjuvants combined with Diphtheria Toxoid administered topically in BALB/c mice after microneedle array pretreatment.
    Pharmaceutical research, 2009
    Co-Authors: Zhi Ding, Gideon F.a. Kersten, Wim Jiskoot, Stefan Romeijn, Y. E. Van Riet, J.a. Bouwstra
    Abstract:

    Purpose In this study, modulation of the immune response against Diphtheria Toxoid (DT) by various adjuvants in transcutaneous immunization (TCI) with microneedle array pretreatment was investigated.

John K. Iskander - One of the best experts on this subject based on the ideXlab platform.